MedTrace Logo

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

NCT01096004 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-12-10

No results posted yet for this study

Summary

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Conditions

Interventions

DRUG

AZD4017

oral suspension, 1200mg, once daily, for 10 days

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Per-Anders Jansson, Ass Prof, MD, PhD · Avdelningen för molekylär och klinisk medicin Lundberglaboratoriet

  • Mikaela Sjöstrand · AstraZeneca

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01096004 on ClinicalTrials.gov